Costs of Illness of Spinal Muscular Atrophy: A Systematic Review

Erik Landfeldt (), Astrid Pechmann, Hugh J. McMillan, Hanns Lochmüller and Thomas Sejersen
Additional contact information
Erik Landfeldt: Karolinska Institutet
Astrid Pechmann: Medical Centre-University of Freiburg
Hugh J. McMillan: Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa
Hanns Lochmüller: Medical Centre-University of Freiburg
Thomas Sejersen: Karolinska Institutet

Applied Health Economics and Health Policy, 2021, vol. 19, issue 4, No 5, 520 pages

Abstract: Abstract Objectives The objective of our study was to conduct a systematic literature review of estimates of costs of illness of spinal muscular atrophy (SMA). Methods We searched MEDLINE (through PubMed), CINAHL, Embase, Web of Science, National Health Service Economic Evaluation Database, and the National Health Service Health Technology Assessment Database for studies published from inception up until 31 August, 2020, reporting direct medical, direct non-medical, and/or indirect costs of any phenotype of SMA. Two reviewers independently screened records for eligibility, extracted the data, and assessed studies for risk of bias using the Newcastle–Ottawa Scale. Costs were adjusted and converted to 2018 US dollars. Results The search identified 14 studies from eight countries (Australia, France, Germany, Italy, Spain, Sweden, the UK, and the USA). The mean per-patient annual direct medical cost of illness was estimated at between $3320 (SMA type III, Italy) and $324,410 (SMA type I, USA), mean per-patient annual direct non-medical cost between $25,880 (SMA types I–III, Spain) and $136,800 (SMA type I, Sweden), and mean per-patient annual indirect cost between $9440 (SMA type I, Germany) and $74,910 (SMA type II, Australia). Most studies exhibited a risk of bias. Conclusions The current body of evidence of costs of illness of SMA is relatively scarce and characterized by considerable variability across geographical settings and disease phenotypes. Our review provides data pertaining to the economic impact of SMA, which is of particular relevance in light of emerging treatments and ongoing research in this field, and underscores the substantial unmet medical need in this patient population.

Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://link.springer.com/10.1007/s40258-020-00624-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:19:y:2021:i:4:d:10.1007_s40258-020-00624-2

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-020-00624-2

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().